The global AI-driven Drug Discovery market size is predicted to grow from US$ 884 million in 2025 to US$ 1643 million in 2031; it is expected to grow at a CAGR of 10.9% from 2025 to 2031.

AI, its end-to-end drug discovery platform using generative artificial intelligence to discover new targets, design new molecules, and predict the outcome of clinical trials.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs.

• For biologics is expected to 381 billion USD in 2022.
• In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.

The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations.

Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

ReportPrime' newest research report, the “AI-driven Drug Discovery Industry Forecast”

looks at past sales and reviews total world AI-driven Drug Discovery sales in 2024, providing a comprehensive analysis by region and market sector of projected AI-driven Drug Discovery sales for 2025 through 2031.

With AI-driven Drug Discovery sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AI-driven Drug Discovery industry.

Key features

This Insight Report provides a comprehensive analysis of the global AI-driven Drug Discovery landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report also analyses the strategies of leading global companies with a focus on AI-driven Drug Discovery portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global AI-driven Drug Discovery market.

Segmentation by Type

• Small Molecule Drug
• Biological Modeling
• Structural Biology
• Others

Segmentation by Application

• Pharmaceutical and Biotechnology Companies
• Research Laboratories

Market by Region

• Americas
• APAC
• Europe
• Middle East & Africa

Companies Coverage

• Entos
• Selvita
• Benevolent
• Exscientia
• Euretos
• Illumina with AstraZeneca
• Novo Nordisk with Microsoft
• Iktos
• Aqemia
• Zephyr AI
• Cyclicarx
• Eli Lilly
• Terray Therapeutics
• Ardigen
• ReviveMed
• Insilico Medicine
• XtalPi
• MindRank
• DP Technology

Key Questions Addressed in this Report